US DISTRICT COURT RULES ONE PULMICORT RESPULES® (BUDESONIDE INHALATION SUSPENSION) PATENT INVALID AND ANOTHER PATENT NOT INFRINGED
AstraZeneca today announced that the United States District Court for the District of New Jersey ruled that AstraZeneca’s US Patent No. 6,598,603 (“the ‘603 patent”), protecting PULMICORT RESPULES in the US, is invalid. The Court further ruled that the generic defendants involved in the litigation do not infringe AstraZeneca’s second patent, US Patent No. 7,524,834 (“the ‘834 patent”).
“Astra